Liquidia (LQDA) Cash from Operations Growth (3y) (2023 - 2026)
Liquidia (LQDA) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 27.85% |
| 10 | Liquidia | 7.39 Bn | 7.17 Bn | 121.79 Mn | 102.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.19% |
| Dec 31, 2025 | 126.45% |
| Sep 30, 2025 | -19.16% |
| Jun 30, 2025 | -67.32% |
| Mar 31, 2025 | -46.38% |
| Dec 31, 2024 | -40.16% |
| Sep 30, 2024 | -62.63% |
| Jun 30, 2024 | -40.00% |
| Mar 31, 2024 | -26.15% |
| Dec 31, 2023 | -4.29% |
| Sep 30, 2023 | 2.59% |
| Jun 30, 2023 | 24.85% |
| Mar 31, 2023 | 16.33% |